Diede Brunen joined BGV as an Analyst in November 2017 and is currently a Senior Associate.
Diede has a broad background in biomedical sciences. He finished the master program for Infection & Immunology (cum laude) at Utrecht University in 2012. A major part of his research was performed at The Hospital for Sick Children in Toronto, Canada.
Diede completed his PhD research on mechanisms of cancer drug resistance in the group of Prof. Dr. René Bernards at The Netherlands Cancer Institute in Amsterdam.
Throughout his time at BGV Diede has played a significant role in deal flow management and company creation for the likes of Genase, Tessellate, Dunad and Artica.
MSc Biomedical Sciences
PhD Biomedical Sciences